<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679497</url>
  </required_header>
  <id_info>
    <org_study_id>RisVac02</org_study_id>
    <secondary_id>EudraCT: 2007-002367-27</secondary_id>
    <nct_id>NCT00679497</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection</brief_title>
  <acronym>RisVac02</acronym>
  <official_title>A Phase I Study of MVA-B in Healthy Volunteers at Low Risk of HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to study a modified pox viral vector considering:

        1. HIV subtype B accounts for the most frequent virus strain in Europe and North America,
           as well as in many parts of the world.

        2. This novel vaccinia construct expressing HIV subtype B gag, pol, env and nef antigens is
           to be studied in humans for the first time.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: proportion of patients with Grade 3 or above local, systemic or other clinical or laboratory adverse events. Adverse events attributable to discontinuation of the immunisation regimen. Immunogenicity: cellular responses (ELISPOT)</measure>
    <time_frame>Safety: at any point of the study; Immunogenicity:week 6/8, 18/20, and at any point following immunisations</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with grade 1 and 2 adverse events within 28 days of a vaccination -antibody responses -cellular responses -intracellular cytokine analysis</measure>
    <time_frame>at any point of the study and at week 6 and 18 for intracellular cytokine analysis</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVA HIV-B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-B</intervention_name>
    <description>Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)
-~ 1 x 10e8 pfu/ml
3 immunisations at week 0, 4 and 16</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>-3 immunisations at week 0, 4 and 16</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female

          -  age between 18 and 55 years on the day of screening

          -  available for follow-up for the duration of the study (52 weeks from screening)

          -  able to give written informed consent

          -  at low risk of HIV and willing to remain so for the duration of the study low risk of
             HIV infection defined as: no history of injecting drug use in the previous ten years
             no gonorrhoea or syphilis in the last six months no high risk partner (e.g. injecting
             drug use, HIV positive partner) either currently or within the past six months no
             unprotected anal intercourse in the last six months no unprotected vaginal intercourse
             outside a relationship with a regular known/presumed HIV negative partner in the last
             six months

          -  willing to undergo a HIV test

          -  willing to undergo a genital infection screen

          -  if heterosexually active female, using an effective method of contraception with
             partner (combined oral contraceptive pill; injectable contraceptive; IUCD; consistent
             record with condoms if using these; physiological or anatomical sterility in self or
             partner) from 14 days prior to the first vaccination until 4 months after the last,
             and willing to undergo urine pregnancy tests prior to each vaccination

          -  if heterosexually active male, using an effective method of contraception with their
             partner from the first day of vaccination until 4 months after the last vaccination

        Exclusion Criteria:

          -  positive for hepatitis B surface antigen, hepatitis C antibody, antibody responses to
             vaccinia or serology indicating active syphilis requiring treatment

          -  pregnant or lactating

          -  clinically relevant abnormality on history or examination including history of
             grand-mal epilepsy, severe eczema, immunodeficiency or use of immunosuppressives in
             preceding 3 months

          -  receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of
             enrolment

          -  receipt of blood products or immunoglobin within 4 months of screening

          -  participation in another trial of a medicinal product, completed less than 30 days
             prior to enrolment

          -  history of severe local or general reaction to vaccination defined as local:
             extensive, indurated redness and swelling involving most of the front-lateral thigh or
             the major circumference of the arm, not resolving within 72 hours general: fever &gt;=
             39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal

          -  HIV 1/2 positive or indeterminate on screening

          -  positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating
             active syphilis requiring treatment

          -  grade 1 routine laboratory parameters

          -  unlikely to comply with protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep M Gatell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9.</citation>
    <PMID>21907749</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>February 21, 2013</last_update_submitted>
  <last_update_submitted_qc>February 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Low risk HIV infection</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

